Skip to main content
D.Western Therapeutics Institute, Inc. logo

D.Western Therapeutics Institute, Inc. — Investor Relations & Filings

Ticker · 4576 ISIN · JP3548740004 T Professional, scientific and technical activities
Open in API
Filings indexed 69 across all filing types
Latest filing 2024-06-07 Regulatory Filings
Country JP Japan
Listing T 4576

About D.Western Therapeutics Institute, Inc.

https://dwti.co.jp/english/

D.Western Therapeutics Institute, Inc. is a biotechnology company focused on the research, discovery, and development of innovative pharmaceutical drugs. The company's core technology is centered on a proprietary compound library with a primary focus on inhibitors, particularly protein kinase inhibitors. Its drug discovery and development business aims to provide patients with more effective and beneficial treatments than conventional drugs. A notable product developed from its research is the ophthalmic solution GLANATEC.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director ("東海財務局長"). The filing reason explicitly states that an event significantly impacting the company's financial condition has occurred, citing provisions of the Financial Instruments and Exchange Act (Article 24-5, Paragraph 4) and related Cabinet Office Ordinance. The content details the early redemption of convertible bonds ("第１回無担保転換社債型新株予約権付社債") on June 7, 2024, and the resulting special loss to be recorded in the second quarter consolidated and non-consolidated financial statements. This type of mandatory, event-driven disclosure in Japan, which is not a standard periodic report (like 10-K or IR), falls under the category of general regulatory announcements or timely disclosures that do not fit other specific categories. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for this type of mandatory, non-periodic disclosure, although it is a specific Japanese filing type (Tanshin/Extraordinary Report). Since 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' it is the best fit among the provided codes.
2024-06-07 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is submitted to the "東海財務局長" (Director of the Tokai Local Finance Bureau) on May 17, 2024. It specifically details the offering of "新株予約権証券" (Stock Acquisition Rights Certificates), including the offering terms, exercise price adjustments, and capital structure implications. This document is a formal regulatory filing related to the issuance of securities, which aligns with the definition of a comprehensive registration or offering document. While it details the terms of a capital raise (CAP), the document itself is a formal registration statement required by financial regulators, which is best classified as a general regulatory filing or a specific type of offering document. Given the options, this is a detailed filing concerning the issuance of stock acquisition rights, which falls under the scope of capital/financing activities, but the document type itself is a formal registration statement. In the context of US-centric classifications (like 10-K, DEF 14A), a Japanese Securities Registration Statement (有価証券届出書) is a mandatory disclosure document. Since there isn't a direct equivalent for a Japanese registration statement, and it details a capital change (issuance of stock acquisition rights), it relates closely to 'CAP' (Capital/Financing Update). However, '有価証券届出書' is a primary disclosure document. If we must choose from the provided list, and considering it is a detailed filing about a specific security offering (Stock Acquisition Rights), it is a comprehensive disclosure related to financing. Since it is not an Annual Report (10-K) or an Interim Report (IR), and it is the primary disclosure document for this offering, it is most accurately categorized as a Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if the specific nature isn't covered. Given the extensive detail on the terms of the new security issuance, 'CAP' is a strong fit, but '有価証券届出書' is a formal registration. Since the document is extremely long (49k chars) and contains the full details of the offering, it is the report itself, not just an announcement of a report (RPA). Based on the content focusing entirely on the terms of issuing new stock acquisition rights, 'CAP' is the most descriptive category for the *subject matter* of the filing, even if the *form* is a registration statement. However, '有価証券届出書' is a mandatory disclosure filing. Given the options, and recognizing this is a primary regulatory disclosure document detailing a financing event, I will lean towards the most specific category related to the event described, which is 'CAP'. If 'CAP' is too narrow for a full registration statement, 'RNS' (Regulatory Filings) is the fallback. Let's re-evaluate: The document is a formal registration statement for the issuance of stock acquisition rights, which is a financing activity. I will classify it as CAP as it is the core subject matter, but acknowledge its nature as a regulatory filing.
2024-05-17 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document text contains the header "第１四半期報告書" (First Quarter Report) and explicitly mentions the period covered: "第27期第１四半期（自 2024年１月１日 至 2024年３月31日）". It also includes a confirmation statement by the CEO regarding the appropriateness of the quarterly report's contents based on financial instruments laws. This structure strongly indicates a comprehensive financial report for an interim period shorter than a year, which corresponds to the Interim / Quarterly Report definition. Although it is a report, the content provided seems to be the certification/cover page of the report rather than the full financial statements. However, given the explicit identification as a "Quarterly Report" and the detailed financial period reference, classifying it as the comprehensive report (IR) is more accurate than classifying it as a mere announcement (RPA/RNS), especially since the document length is not extremely short (600 chars) and it contains substantive confirmation text, not just a link/notice of publication. Therefore, the appropriate code is IR.
2024-05-13 Japanese
四半期報告書－第27期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Tokai Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement for the first quarter of the 27th fiscal year (January 1, 2024, to March 31, 2024). It also includes management analysis and notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-13 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the Annual General Meeting (AGM) held on March 27, 2024, in accordance with financial regulations. Section 2 details the resolutions passed, specifically the election of two directors (日高有一 and 松原さや子), and provides the voting results (votes for, against, and the resulting approval percentage). This content—reporting the results of shareholder votes from a general meeting—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the primary function here is reporting the *results* of the vote, not providing the meeting materials (AGM-R) or proxy information (PSI).
2024-03-28 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document text contains Japanese characters and includes the title "有価証券報告書（通常方式）" which translates to "Securities Report (Regular Method)". It also references the "金融商品取引法" (Financial Instruments and Exchange Act) and explicitly states that the representative director confirmed the appropriateness of the "有価証券報告書" (Securities Report) for the fiscal year ending December 31, 2023. A Securities Report in the Japanese regulatory context is equivalent to the comprehensive annual filing, which corresponds to the US 10-K filing type. Although the document itself appears to be a confirmation statement regarding the filing, the core subject matter is the annual Securities Report (10-K equivalent). Given the options, 10-K is the most appropriate classification for the underlying document being confirmed, as it is the official yearly report covering full financial performance. FY 2023
2024-03-27 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.